WEIGH RISKS VS BENEFITS
Lynparza 50mg is unsafe to use during pregnancy. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk, for example in life-threatening situations.
caution
Lynparza 50mg is probably unsafe to use during lactation. Limited human data suggest that the drug could represent a significant risk to the baby.
Driving
It is not known whether Lynparza 50mg alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Kidney
Lynparza 50mg is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Lynparza 50mg may not be needed in these patients. Please consult your doctor.
Liver
There is limited information available on the use of Lynparza 50mg in patients with liver disease. Please consult your doctor.
Composition Olaparib 50mg
Substitutes Olanib 50mg 112s,Lynparza 50mg 112s (RU)
Shipping class Room Temperature
Medicine Overview of Lynparza 50mg 112s Capsules
uses
Uses of Lynparza 50mg 112s Capsules
Lynparza 50mg is a prescription medicine used to treat adult women who are in advanced ovarian cancer stage.
uses
Lynparza 50mg 112s Capsules side effects
Common
Decreased hemoglobin, Fatigue/asthenia, Nausea, Mean corpuscular volume elevation, Decreased lymphocytes, Abdominal pain/discomfort, Vomiting, Anemia, Diarrhea, Increased serum creatinine, Decreased platelets, Nasopharyngitis/URTI, Dyspepsia, Decrease ANC, Decreased appetite, Myalgia, Arthralgia/musculoskeletal pain, Hypersensitivity (rash, dermatitis), Cough, Thrombocytopenia, Dysgeusia, Lymphopenia, Dizziness, Stomatitis, Upper abdominal pain.
uses
How to use Lynparza 50mg 112s Capsules
For advanced Ovarian cancer, 8 capsules twice daily (400 mg per dose) with or without food. Lynparza 50mg dosages must be taken according to professional physician??s instructions. Dosages may vary according to patient conditions.
How Lynparza 50mg 112s Capsules works
FDA approves Olaparib for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy.
